MapLight Therapeutics (MPLT) Income from Continuing Operations (2024 - 2026)

MapLight Therapeutics (MPLT) posted Income from Continuing Operations of 81207000.0 for Q4 2025, down 138.36% sequentially from 34069000.0 in Q3 2025, and down 276.34% YoY from 46050948.62 in Q4 2024.

MapLight Therapeutics (MPLT) Income from Continuing Operations (2024 - 2026) Analysis & Trends

MapLight Therapeutics has reported Income from Continuing Operations for 2 years, with the latest figure at 81207000.0 in Q4 2025.

  • Quarterly Income from Continuing Operations fell 276.34% year-over-year to 81207000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 156967000.0 (changed N/A YoY) and the FY2025 annual result came in at 176190000.0, down 93.77% from the prior year.
  • Income from Continuing Operations retreated to 81207000.0 in Q4 2025 per MPLT's latest filing, from 34069000.0 in the prior quarter.
  • Over five years, Income from Continuing Operations peaked at 20113000.0 in Q3 2024 and troughed at 81207000.0 in Q4 2025.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Income (Continuing) (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn 1.10 Bn
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 1.30 Bn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn 482.00 Mn
4 Revolution Medicines 43.64 Bn 43.64 Bn - -644.37 Mn
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 237.01 Mn
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn -3,096.02
7 Royalty Pharma 33.72 Bn 35.84 Bn - 81.49 Mn
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn 164.49 Mn
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn -13.27 Mn
10 MapLight Therapeutics 533.88 Mn 533.88 Mn - -152.33 Mn

Historic Data

Download Data
DateValue
Jun 30, 2026 -152.33 Mn
Dec 31, 2025 -81.21 Mn
Sep 30, 2025 -34.07 Mn
Dec 31, 2024 -21.58 Mn
Sep 30, 2024 -20.11 Mn